Skip to Content

DexCom Inc

DXCM: XNAS (USA)
View Stock Summary
Morningstar Rating for Stocks Fair Value Economic Moat Capital Allocation
$168.00NgvrRlqlmncgw

Dexcom Poised for Further Adoption of G7

Business Strategy and Outlook

Dexcom enjoys a well-established track record for introducing the most precise sensors for use in its continuous glucose monitors. On the strength of its technology, Dexcom has captured an impressive slice of this CGM market, but a recent wave of innovation in the diabetes device market has intensified competitive pressure. Nonetheless, Dexcom has done a credible job of adapting and fending off competition from Abbott and Medtronic.

Free Trial of Morningstar Investor

Get our analysts’ objective, in-depth, and continuous investment coverage of DXCM so you can make buy / sell decisions free of market noise.

Start Free Trial

Sponsor Center